The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2021 | Phase III trial of ruxolitinib plus parsaclisib in treatment-naïve myelofibrosis
Abdulraheem Yacoub
• 4 Jun 2021
Abdulraheem Yacoub, MD, University of Kansas Medical Center, Kansas City, MO, gives an overview of a Phase III randomized double-blind trial (NCT04551066) which will explore ruxolitinib plus parsaclisib in patients with myelofibrosis who are naïve to JAK and PI3K inhibitors. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
